Phase 0 1 trial
Phase 0
NCT06204614 Jun 2024 → Jul 2028 expected infiltrating bladder urothelial carcinoma Brigham and Women's Hospital
Enrolling by invitation
No outcome recorded
Phase 1 14 trials
Phase 1
NCT05567185 Mar 2023 → Mar 2025 overdue urinary bladder cancer Janssen Pharmaceutical K.K.
Active not recruiting
No outcome recorded
Phase 1
NCT04963153 Jul 2022 → Dec 2026 expected ureter cancer , urethra cancer , urothelial carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04330248 Mar 2020 → Jun 2022 —
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed
No outcome recorded
Phase 1
NCT03587363 Dec 2018 → Dec 2020 —
Janssen Research & Development, LLC
Terminated
No outcome recorded
Phase 1
NCT03547037 Aug 2018 → Jul 2022 neoplasm Janssen Pharmaceutical K.K.
Completed
No outcome recorded
Phase 1
NCT03238196 Aug 2017 → Apr 2021 breast cancer Vanderbilt-Ingram Cancer Center
Completed
No outcome recorded
Phase 1
NCT03135106 Apr → Sep 2017 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT03066687 Mar → May 2017 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT02692677 Mar → Aug 2016 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT02466815 Jun → Aug 2015 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT02218073 Oct → Dec 2014 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT02231489 Sep → Nov 2014 —
Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT01962532 Aug 2013 → Jan 2016 gastroesophageal junction adenocarcinoma , lymphoma Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 1
NCT01703481 Jun 2012 → Jul 2017 lymphoma Janssen Research & Development, LLC
Completed
No outcome recorded
Show 4 more trials Phase 1/2 4 trials
Phase 1/2
NCT05316155 Apr 2022 → Mar 2028 expected non-invasive bladder urothelial carcinoma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 1/2
NCT03732703 Apr 2019 → Dec 2024 refractory plasma cell neoplasm Multiple Myeloma Research Consortium
Completed
No outcome recorded
Phase 1/2
NCT03473743 Apr 2018 → Sep 2022 overdue urothelial carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1/2
NCT02421185 May 2015 → May 2019 hepatocellular carcinoma Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 2 17 trials
Phase 2
NCT05859334 Jan 2024 → Oct 2026 expected grade II glioma , grade III glioma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 2
NCT05564416 Oct 2023 → Jan 2024 infiltrating bladder urothelial carcinoma , renal pelvis/ureter urothelial carcinoma National Cancer Institute (NCI)
Withdrawn
No outcome recorded
Phase 2
NCT06511648 Mar 2023 → Jul 2026 overdue infiltrating bladder urothelial carcinoma Spanish Oncology Genito-Urinary Group
Recruiting
No outcome recorded
Phase 2
NCT04917809 Feb 2022 → Aug 2026 overdue urinary bladder cancer Memorial Sloan Kettering Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT04754425 Jul 2021 → Feb 2026 castration-resistant prostate carcinoma , metastatic carcinoma in the bone , prostate adenocarcinoma , prostate small cell carcinoma M.D. Anderson Cancer Center
Terminated
No outcome recorded
Phase 2
NCT03999515 Apr 2020 → Jun 2021 castration-resistant prostate carcinoma , metastatic prostate carcinoma , prostate adenocarcinoma University of Washington
Terminated
No outcome recorded
Phase 2
NCT04172675 Feb 2020 → Jul 2024 urinary bladder neoplasm Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 2
NCT04083976 Nov 2019 → Dec 2023 neoplasm Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 2
NCT06308822 Aug 2018 → Jul 2022 overdue adult lymphoma , plasma cell myeloma , refractory malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT06351371 Jul 2018 → Jun 2022 overdue cancer National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT03210714 Jun 2018 → Sep 2023 overdue Ewing sarcoma/peripheral primitive neuroectodermal tumor , Langerhans cell histiocytosis , Wilms tumor , childhood ependymoma +9 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT03155620 Jul 2017 → Mar 2025 overdue Ewing sarcoma , Langerhans cell histiocytosis , Wilms tumor , conventional osteosarcoma +13 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT02952573 Jun 2017 → Nov 2018 plasma cell myeloma University Health Network, Toronto
Terminated
No outcome recorded
Phase 2
NCT02925234 Aug 2016 → Sep 2027 expected cancer The Netherlands Cancer Institute
Recruiting
No outcome recorded
Phase 2
NCT02699606 Jul 2016 → Oct 2021 neoplasm Janssen Research & Development, LLC
Completed
No outcome recorded
Phase 2
NCT02465060 Aug 2015 → Dec 2026 expected breast carcinoma , carcinoma of esophagus , cervical carcinoma , colon carcinoma +17 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT02365597 Apr 2015 → Sep 2022 overdue urothelial carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Show 7 more trials Phase 3 3 trials
Phase 3
NCT06919965 Sep 2025 → Apr 2028 expected urinary bladder neoplasm Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT06319820 Apr 2024 → Jun 2028 expected urinary bladder carcinoma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT03390504 Mar 2018 → Apr 2024 overdue urothelial carcinoma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase not applicable 1 trial
— NCT06328491 May → Aug 2022 malignant sex cord stromal tumor of ovary University Health Network, Toronto
Completed
No outcome recorded
Phase not stated 1 trial
— NCT03825484 — —
Janssen Scientific Affairs, LLC
Approved for marketing
No outcome recorded